BONTAC® NMN: The Documented Source Behind Novera

1Professional NMN · Who makes your NMN?

BONTAC Innovation. Japanese Manufacturing. Novera Verification.

Novera begins with BONTAC® β-NMN and completes finished-product manufacturing in Japan under certified GMP standards. Each capsule provides 500 mg of NMN, and the documentation for every batch is available for you to verify. For the first time, Novera can name BONTAC directly to consumers as its source — under BONTAC’s first direct-to-consumer authorization of its kind.

BONTAC® β-NMN Finished in Japan 99.9% Batch Purity Documents Available
Shop Novera NMN Source to Bottle Verify Your Batch

2The BONTAC story

A Pioneer in Enzymatic NMN Manufacturing.

Founded in 2012, BONTAC specializes in the biosynthesis of coenzymes. The company describes itself as an early pioneer of large-scale NMN production and uses advanced fully enzymatic manufacturing together with its Bonpure® seven-step purification technology.

Advanced enzymatic processDeveloped for efficient, high-purity coenzyme production.
Bonpure® purificationA proprietary seven-step purification approach.
NMN-focused innovationA portfolio of patent applications related to NMN and coenzyme production.
Documented raw materialIdentity and purity are evaluated through product and batch documentation.
Explore NMN & NAD+ Science NMN vs. NR vs. NAD+

3Published in Cell · 2018

BONTAC NMN Was Used in Research Co-Authored by Harvard’s David Sinclair.

BONTAC supplied the NMN used by the research team in a 2018 preclinical study published in Cell and co-authored by Harvard Medical School researcher David A. Sinclair. The study’s reported NMN-treatment findings were therefore generated using BONTAC-supplied NMN.

View Page 89 of the Study

Please note: This was preclinical research. The finished Novera product was not evaluated in this study. No endorsement of Novera by the study’s authors, Harvard Medical School or Cell is stated or implied.

4Documented in the methods

The Source Is Named Directly.

The article’s Key Resources Table identifies the material used by the research team. The relevant entry appears on page 89 of the published PDF:

Reagent or resourceSourceIdentifier
Nicotinamide mononucleotideBontac Bio-Engineering, ChinaN/A

This supplier entry establishes that the NMN administered in the study’s NMN-treatment experiments came from BONTAC. Accordingly, the NMN-treatment observations reported by the authors were obtained using BONTAC-supplied material.

Key Resources Table · Page 89. This is a faithful text reproduction of the supplier entry; consult the complete publication for full methods and context.

Open the Published PDF

5What the study shows

What the Study Shows — and What It Doesn’t.

Peer-reviewed publicationThe work appeared in the scientific journal Cell in 2018.
Named NMN supplierThe Key Resources Table lists Bontac Bio-Engineering as the source of the NMN used in the treatment experiments.
Research teamDavid A. Sinclair of Harvard Medical School is among the study’s authors.
Preclinical, not a product trialThe research was not a clinical trial and did not test the finished Novera product.

The NMN used in this research was supplied by BONTAC — the same source Novera names on every bottle. Why settle for an unnamed NMN source?

Das A, Huang GX, Bonkowski MS, et al. Impairment of an Endothelial NAD+-H₂S Signaling Network Is a Reversible Cause of Vascular Aging. Cell. 2018;173(1):74–89.e20. doi:10.1016/j.cell.2018.02.008.

Research clarification: The cited study evaluated BONTAC-supplied NMN, not the finished Novera product. The study was preclinical. No endorsement of Novera by the study’s authors, Harvard Medical School or Cell is stated or implied. This content is educational and is not intended to diagnose, treat, cure or prevent any disease.